...IDBE completed its stock acquisition of Intellivax, a developer of influenza vaccines, for 4 million shares... ...2, 2001). IDBE has 25.6 million shares outstanding. ID Biomedical Corp. (IDBE; TSE:IDB), Burnaby, B.C. Intellivax International Inc....
...CSO of Intellivax International Inc. ; David Burt as VP of research, formerly VP of research at Intellivax... ...Gregory White as VP of process development, formerly VP of development and quality systems at Intellivax... ...Fries as VP of clinical and regulatory affairs, formerly VP of clinical and regulatory at Intellivax
WIR...
...system and adjuvant Indication: Prevent influenza infection End point: Safety and immunogenicity Status: Phase I Intellivax... ...circulating hemagglutinin-specific antibodies. Data were presented at the Conference on Vaccine Research in Arlington, Va. Intellivax...
...IDBE will acquire intranasal vaccines developer Intellivax for 4 million shares, or about $12.1 million using... ...for 4 million shares, or about $12.1 million using IDBE's Friday closing price of $3.03. Intellivax... ...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
...ID Biomedical (IDBE; TSE:IDB) will acquire intranasal vaccines developer Intellivax for 4 million shares, or about... ...4 million shares, or about $12.5 million using IDBE's Tuesday morning NASDAQ price of $3.125. Intellivax... ...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
...IDBE completed its stock acquisition of Intellivax, a developer of influenza vaccines, for 4 million shares... ...2, 2001). IDBE has 25.6 million shares outstanding. ID Biomedical Corp. (IDBE; TSE:IDB), Burnaby, B.C. Intellivax International Inc....
...CSO of Intellivax International Inc. ; David Burt as VP of research, formerly VP of research at Intellivax... ...Gregory White as VP of process development, formerly VP of development and quality systems at Intellivax... ...Fries as VP of clinical and regulatory affairs, formerly VP of clinical and regulatory at Intellivax
WIR...
...system and adjuvant Indication: Prevent influenza infection End point: Safety and immunogenicity Status: Phase I Intellivax... ...circulating hemagglutinin-specific antibodies. Data were presented at the Conference on Vaccine Research in Arlington, Va. Intellivax...
...IDBE will acquire intranasal vaccines developer Intellivax for 4 million shares, or about $12.1 million using... ...for 4 million shares, or about $12.1 million using IDBE's Friday closing price of $3.03. Intellivax... ...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...
...ID Biomedical (IDBE; TSE:IDB) will acquire intranasal vaccines developer Intellivax for 4 million shares, or about... ...4 million shares, or about $12.5 million using IDBE's Tuesday morning NASDAQ price of $3.125. Intellivax... ...trials of its intranasal subunit vaccine to prevent influenza, with results expected later this year. Intellivax...